Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors - Contact The Gross Law Firm

1. EPIX faces a class action due to misleading claims about masofaniten's efficacy. 2. Claims suggest masofaniten lacks benefit with enzalutamide against prostate cancer. 3. Study unlikely to meet Phase 2 primary endpoint, impacting investors' trust. 4. Shareholders urged to register by March 25, 2025, for potential recovery. 5. The firm's reputation may affect investor confidence in EPIX's future prospects.

Legal

75

4m saved

Insight

Article

FAQ

Why Very Bearish?

The class action lawsuit suggests serious regulatory and clinical efficacy concerns. Past instances show significant stock declines following lawsuits or negative efficacy data.

How important is it?

Class actions can lead to substantial financial implications for EPIX investors. Significant scrutiny is expected on company's statements and future clinical trials.

Why Short Term?

Immediate legal concerns will likely impact share price sharply. Historical trends indicate lawsuits often lead to quick declines.

Related Companies

EPIX ESSA

NEW YORK, Feb. 13, 2025 /PRNewswire/ --

The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).

Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=128948&from=4

CLASS PERIOD:

December 12, 2023 to October 31, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE:

March 25, 2025. Shareholders should not delay in registering for this class action. Register your information here:

https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=128948&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 25, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm